Brought to you by 
Geron grants Janssen Biotech global rights to imetelstat; deal terminated
30 Jan 2023
Executive Summary
Just a couple weeks after the FDA removed a clinical hold on its modified oligonucleotide imetelstat, cancer-focused Geron Corp. licensed Janssen Biotech Inc. exclusive worldwide rights to develop and commercialize the telomerase inhibitor (GRN163L) for oncology indications, including myeloid malignancies, and all other human therapeutic uses. Janssen will pay $35mm up front initially, up to $900mm in development, regulatory, and commercial milestones, plus sales royalties.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Geron grants Janssen Biotech global rights to imetelstat; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice